New Content  edit
Get The App!

Loading the player...
Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. Srdan Verstovsek discusses Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib at ASCO 2017. For the ability to view on your mobile phone please visit us at MinuteCE.com.

This transcript is software driven, please understand there may be errors.  Should any inaccuracies or omissions be found, please notify transcripts@MedEdOTG.com for correction.

Hello. My name is Srdan Verstovsek, I'm professor of medicine in the leukemia department at Andy Anderson Cancer Center in Houston, Texas. I'm here in Chicago at ASCO 2017 Annual Meeting. I'm presenting the results of the phase three randomized study in patients that have myelofibrosis, and who were previously treated with ruxolitinib. The study compares the efficacy and safety of a medication called momelotinib, to best available therapy. In myelofibrosis, we have only one therapy approved so far, and this is ruxolitinib a JAK inhibitors that improve the spleen size and quality of life of patients with myelofibrosis, but on the other hand, can cause some anemia, and it does not improve the blood cell count. Momelotinib has been developed as a new JAK inhibitor that is now being tested in the second line setting, after ruxolitinib to possibly improve not just the symptoms in the spleen, but also the anemia.

In these randomized studies, patients were equally randomized to momelotinib or best available therapy. And results show that the spleen response between the two was no different on the other hand, the momelotinib provides superiority in controlling myelofibrosis related symptoms. Finally, on the question of anemia, transfusion independence was achieved in many more patients on momelotinib arm. Combination of these benefits possibly can be useful in the future for patients with myelofibrosis. Unfortunately, the final results, because of inability of momelotinib to improve the spleen size, was negative. Further development of momelotinib will be considered in the future. Thank you.